September 11, 2019
In this phase III trial, investigators assessed the clinical efficacy and safety of durvalumab with or without tremelimumab with etoposide and carboplatin or cisplatin chemotherapy followed by durvalumab with or without tremelimumab maintenance therapy compared with EP alone as first-line treatment in extensive-stage small-cell lung cancer.
August 05, 2019
A phase III trial found bevacizumab and pemetrexed were effective as a maintenance therapy, but researchers do not recommend it to treat non–small-cell lung cancer.
June 21, 2019
Lurbinectedin may represent a new treatment option as second-line therapy for patients with small-cell lung cancer.
May 20, 2019
A new study identified several T-cell antigens that are shared between tumor tissue and skin in a cohort of patients with non–small-cell lung cancer who were treated with anti–PD-1 therapy.
September 05, 2018
A 17-gene signature derived from circulating tumor cells was found to correlate with response to therapy in patients with breast cancer.
April 30, 2018
Alectinib offered significantly improved outcomes over standard chemotherapy in patients with ALK-positive non–small-cell lung cancer who had progressed on crizotinib therapy.
February 16, 2018
Maintenance therapy with pazopanib significantly prolonged progression-free survival in patients with extensive-disease small-cell lung cancer, but with toxicity.
November 10, 2017
NY-ESO-1 SPEAR T-cell therapy showed promising results and was reasonably safe in patients with synovial sarcoma, according to a new study. The addition of fludarabine may be important to achieving those positive results.
November 06, 2017
Novartis has submitted an application to the FDA to extend the indications for its CAR T-cell therapy tisagenlecleucel (Kymriah) for its use in adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.
October 10, 2017
The second-generation EGFR tyrosine kinase inhibitor dacomitinib significantly improved progression-free survival over gefitinib as a first-line therapy for EGFR–positive non–small-cell lung cancer, according to a randomized phase III trial.